Cite

    Marco Galluzzo et al.. “In which patients the best efficacy of secukinumab? Update of a real-life analysis after 136 weeks of treatment with secukinumab in moderate-to-severe plaque psoriasis.” Expert opinion on biological therapy, vol. 20, 2020, pp. 173–182. http://access.bl.uk/ark:/81055/vdc_100099951035.0x00003c